drugset / Trial / NCT03136068
Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation
Phase 4
Completed
178 enrolled
University of California, San Francisco
FPA Women's Health · collabOregon Health and Science University · collabSociety of Family Planning · collab
RandomizedParallel-groupQuadruple-blindOther
Summary
This is a research study to measure the effect of digoxin injection on Dilation and Evacuation (D\&E) procedure duration. Digoxin is the most commonly used feticidal agent among family planning subspecialists, and is commonly used for a variety of reasons including provider preference, patient preference, and concerns over legal status of later D\&E procedures. There have been several studies on digoxin administration, adverse effects, and impact on the D\&E procedure, but doctors want to clarify how digoxin effects D\&E procedure time, if at all.
Timeline
- Start
- 2017-02-23
- Primary completion
- 2018-05-31
- Completion
- 2018-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Digoxin | Other / unclassified | 1 mg | Other |
Indications
No indication recorded.